ADOLESCENT PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (AD)

Clinical trials for ADOLESCENT PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (AD) explained in plain language.

Never miss a new study

Get alerted when new ADOLESCENT PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (AD) trials appear

Sign up with your email to follow new studies for ADOLESCENT PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (AD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Completed 1

New oral drug aims to tame severe eczema in teens

Disease control Completed

This study tests an experimental oral medication called QY201 in adolescents aged 12 to 17 with moderate to severe atopic dermatitis (eczema). Participants take either 10 mg or 20 mg of QY201 twice daily for 28 days. The main goal is to understand how the drug moves through the b…

Matched conditions: ADOLESCENT PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (AD)

Phase: PHASE2 • Sponsor: E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. • Aim: Disease control

Last updated Jul 19, 2026 00:00 UTC

ADOLESCENT PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (AD)

Get alerted when new ADOLESCENT PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (AD) trials appear

New oral drug aims to tame severe eczema in teens